Results 41 to 50 of about 21,002 (228)

Evidence based medicine and pharmacoeconomics [PDF]

, 2014
Unfortunatelly, the exact cost-reduction can not be calculated due to the type of reduction (mainly qualitative reduction, meaning time consuming, health benefit for the baby etc).
Trajkova, Kornelija, Zisovska, Elizabeta
core   +2 more sources

Comparing the cost-benefit of breast cancer screening programs in rural and urban areas across four economic zones in China: a Markov modeling analysis

BMC Public Health
Background This study assessed the effectiveness and cost-effectiveness of breast cancer screening across rural and urban regions in China’s four economic zones.
Dachuang Zhou, Kejia Zhou, Wenjuan Wang, Hanqiao Shao, Hongliu Zhang, Wenxi Tang   +5 more
doaj   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Advances in Pharmacoeconomics

, 2020
Pharmacoeconomics refers to the scientific discipline that compares the value of one pharmaceutical drug or drug therapy to another. It is a sub-discipline of health economics. A pharmacoeconomic study evaluates the cost (expressed in monetary terms) and
Raju Kandimalla, Klas Kellerborg, Cathrine Elgaard Jensen, William Hollingworth, Afschin Gandjour, Agata Łaszewska   +5 more
core   +1 more source

Is it time for China to prioritize pan-genotypic regimens for treating patients with hepatitis C?

Cost Effectiveness and Resource Allocation
Introduction The treatment of hepatitis C has entered the pan-genotypic era, but the effectiveness is not good for the genotype 3b patients who have a large proportion in China.
Yusi Tu, Xiangyan Tang, Dachuang Zhou, Hanqiao Shao, Leyi Liang, Wenxi Tang   +5 more
doaj   +1 more source

Experience and perspectives of distance learning of pharmacists-interns in the system of continuous education

Фармацевтичний журнал, 2019
Modernization of the educational process at the postgraduate stage using modern computer technologies is extremely urgent. The purpose of the study was to analyze the experience of distance learning of pharmacists-interns at the department of ...
Ya. O. Grynkiv, O. М. Zaliska, O. E. Sichkoriz   +2 more
doaj   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Pharmacoeconomics: friend or foe? [PDF]

, 2006
The financial constraints faced by most health systems today make it necessary for manufacturers of new, expensive drugs to demonstrate value for money. This paper describes the different types of economic evaluation; the increasing use of these analysis
Drummond, M.
core   +1 more source

Precision medicine in paediatrics: Progress and priorities

British Journal of Clinical Pharmacology, EarlyView.
Precision medicine is revolutionizing personalized healthcare, advancing both diagnostics and therapeutics at an unprecedented pace. Reviewing the paediatric applications of pharmacometrics, pharmacogenomics and advanced therapy medicinal products highlights not only the relevance of these exciting innovations to frontline care but also the significant
Nicola Husain, Claire Booth, Joseph F. Standing, Charlotte I. S. Barker   +3 more
wiley   +1 more source

Capacity building in medicines development and regulation in Africa—Overview on recent progress

British Journal of Clinical Pharmacology, EarlyView.
Aims Despite advances in health research and digital innovation, many African countries continue to face substantial resource constraints, fragmented capacity‐building efforts and a shortage of skilled professionals in medicines development and regulatory science.
Tirhani Maluleke, Emile Malan, Michael Reid, Patrick Bouic, Haylene Nell, Goonaseelan Pillai, Catriona Waitt, Bernd Rosenkranz   +7 more
wiley   +1 more source